CTOs on the Move

Ovid Therapeutics

www.ovidrx.com

 
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovidrx.com
  • 1460 Broadway
    New York, NY USA 10036
  • Phone: 646.661.7661

Executives

Name Title Contact Details
Stephanie Licata
 VP, Program Leadership & Portfolio Management Profile

Funding

Ovid Therapeutics raised $75M on 08/11/2015
Ovid Therapeutics raised $25.86M on 01/23/2017
Ovid Therapeutics raised $25M on 02/26/2019
Ovid Therapeutics raised $20M on 02/26/2019

Similar Companies

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

Hci Medical

Hci Medical is a Conrad, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lightning Step

Lightning Step is the only all-in-one enterprise software for behavioral health and addiction treatment centers created by treatment professionals. The solution brings together the fundamentals required to operate and grow a successful facility in today`s world, integrating CRM, EMR, and RCM systems and removing the cross-communication pain points of using multiple platforms. Enjoy a smoother operation with one system, one login, one price.

BodyMedia

BodyMedia is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pittsburgh, PA. To find more information about BodyMedia, please visit www.bodymedia.com

Barbara Davis Ct Chldhd Diabts

Barbara Davis Ct Chldhd Diabts is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.